Other languages Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
10.36 ^USD	-0.29%		-5.65%	-7.75%

May. 30	Transcript : Roivant Sciences Ltd., Q4 2024 Earnings Call, May 30, 2024
May. 30	Roivant Sciences' Fiscal Q4 Net Loss Widens, Revenue Rises	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Roivant Sciences : 4Q2023 Earnings Call Presentation	May. 30
Transcript : Roivant Sciences Ltd., Q4 2024 Earnings Call, May 30, 2024	May. 30
Roivant Sciences' Fiscal Q4 Net Loss Widens, Revenue Rises	May. 30
Futures Decline Pre-Bell as Traders Await Key Economic Reports; Asia Down, Europe Rises	May. 30
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update	May. 30
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update	May. 30
Transcript : Roivant Sciences Ltd. Presents at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, May-20-2024 09:00 AM	May. 20
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024	May. 16
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	Apr. 05
Moderna Suffers Setback in Lawsuit by Arbutus	Apr. 04
Moderna shares fall after judge sides with Arbutus in patent fight	Apr. 03
Deutsche Bank Raises Roivant Sciences' Price Target to $15 From $14, Maintains Buy Rating	Apr. 03
Goldman Sachs Raises Roivant Sciences' Price Target to $18 From $16, Maintains Buy Rating	Apr. 03
HC Wainwright Raises Roivant Sciences Price Target to $18 From $17, Maintains Buy Rating	Apr. 03
Tesla, UnitedHealth Group fall; Roivant, Valero rise, Tuesday, 4/2/2024	Apr. 02
Roivant Sciences : NIU Phase 2 Topline Results	Apr. 02
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise	Apr. 02
Transcript : Roivant Sciences Ltd. - Special Call	Apr. 02
Roivant Sciences Ltd. announces an Equity Buyback for $1,500 million worth of its shares.	Apr. 02
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million	Apr. 02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Other languages

Filters